Clinical Pharmacogenetics

David A. Flockhart, Leif Bertilsson

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

This chapter discusses various aspects of clinical pharmacogenetics. In the area of pharmacology, the identification of the series of proteins in the familiar pharmacologic cascade essentially identified not only a series of targets for drugs but also a series of genetic targets that might contribute to interindividual variability in drug response. Pharmacologically, significant genetic variation has been described at every point of the cascade leading from the pharmacokinetics of drug absorption to the pharmacodynamics (PD) of drug effect. One of the most well-known polymorphisms relevant to PD response is in the aldehyde dehydrogenase gene. The gene encoding the CYP2D6 enzyme is localized on chromosome 22. By using restriction fragment length polymorphism analysis and the allele-specific polymerase chain reaction, three major mutant alleles were found in Caucasians. One of the most developed examples of clinical pharmacogenomics involves the polymorphism of thiopurine S-methyltransferase. The combined variants in drug metabolism and receptor gene are elaborated in the chapter. In the development of new pharmacogenetic tests, as for any other clinically applied test, assay sensitivity, specificity, and positive predictive value need to be scrutinized rigorously.

Original languageEnglish
Title of host publicationPrinciples of Clinical Pharmacology
PublisherElsevier Inc.
Pages179-195
Number of pages17
ISBN (Print)9780123694171
DOIs
StatePublished - 2007

Fingerprint

Pharmacogenetics
thiopurine methyltransferase
Pharmaceutical Preparations
Alleles
Genes
Drug Receptors
Chromosomes, Human, Pair 22
Cytochrome P-450 CYP2D6
Aldehyde Dehydrogenase
Restriction Fragment Length Polymorphisms
Pharmacokinetics
Pharmacology
Sensitivity and Specificity
Polymerase Chain Reaction
Enzymes
Proteins

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Flockhart, D. A., & Bertilsson, L. (2007). Clinical Pharmacogenetics. In Principles of Clinical Pharmacology (pp. 179-195). Elsevier Inc.. https://doi.org/10.1016/B978-012369417-1/50053-5

Clinical Pharmacogenetics. / Flockhart, David A.; Bertilsson, Leif.

Principles of Clinical Pharmacology. Elsevier Inc., 2007. p. 179-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Flockhart, DA & Bertilsson, L 2007, Clinical Pharmacogenetics. in Principles of Clinical Pharmacology. Elsevier Inc., pp. 179-195. https://doi.org/10.1016/B978-012369417-1/50053-5
Flockhart DA, Bertilsson L. Clinical Pharmacogenetics. In Principles of Clinical Pharmacology. Elsevier Inc. 2007. p. 179-195 https://doi.org/10.1016/B978-012369417-1/50053-5
Flockhart, David A. ; Bertilsson, Leif. / Clinical Pharmacogenetics. Principles of Clinical Pharmacology. Elsevier Inc., 2007. pp. 179-195
@inbook{e4820cd4168b4c4d82039be7e952cb02,
title = "Clinical Pharmacogenetics",
abstract = "This chapter discusses various aspects of clinical pharmacogenetics. In the area of pharmacology, the identification of the series of proteins in the familiar pharmacologic cascade essentially identified not only a series of targets for drugs but also a series of genetic targets that might contribute to interindividual variability in drug response. Pharmacologically, significant genetic variation has been described at every point of the cascade leading from the pharmacokinetics of drug absorption to the pharmacodynamics (PD) of drug effect. One of the most well-known polymorphisms relevant to PD response is in the aldehyde dehydrogenase gene. The gene encoding the CYP2D6 enzyme is localized on chromosome 22. By using restriction fragment length polymorphism analysis and the allele-specific polymerase chain reaction, three major mutant alleles were found in Caucasians. One of the most developed examples of clinical pharmacogenomics involves the polymorphism of thiopurine S-methyltransferase. The combined variants in drug metabolism and receptor gene are elaborated in the chapter. In the development of new pharmacogenetic tests, as for any other clinically applied test, assay sensitivity, specificity, and positive predictive value need to be scrutinized rigorously.",
author = "Flockhart, {David A.} and Leif Bertilsson",
year = "2007",
doi = "10.1016/B978-012369417-1/50053-5",
language = "English",
isbn = "9780123694171",
pages = "179--195",
booktitle = "Principles of Clinical Pharmacology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Clinical Pharmacogenetics

AU - Flockhart, David A.

AU - Bertilsson, Leif

PY - 2007

Y1 - 2007

N2 - This chapter discusses various aspects of clinical pharmacogenetics. In the area of pharmacology, the identification of the series of proteins in the familiar pharmacologic cascade essentially identified not only a series of targets for drugs but also a series of genetic targets that might contribute to interindividual variability in drug response. Pharmacologically, significant genetic variation has been described at every point of the cascade leading from the pharmacokinetics of drug absorption to the pharmacodynamics (PD) of drug effect. One of the most well-known polymorphisms relevant to PD response is in the aldehyde dehydrogenase gene. The gene encoding the CYP2D6 enzyme is localized on chromosome 22. By using restriction fragment length polymorphism analysis and the allele-specific polymerase chain reaction, three major mutant alleles were found in Caucasians. One of the most developed examples of clinical pharmacogenomics involves the polymorphism of thiopurine S-methyltransferase. The combined variants in drug metabolism and receptor gene are elaborated in the chapter. In the development of new pharmacogenetic tests, as for any other clinically applied test, assay sensitivity, specificity, and positive predictive value need to be scrutinized rigorously.

AB - This chapter discusses various aspects of clinical pharmacogenetics. In the area of pharmacology, the identification of the series of proteins in the familiar pharmacologic cascade essentially identified not only a series of targets for drugs but also a series of genetic targets that might contribute to interindividual variability in drug response. Pharmacologically, significant genetic variation has been described at every point of the cascade leading from the pharmacokinetics of drug absorption to the pharmacodynamics (PD) of drug effect. One of the most well-known polymorphisms relevant to PD response is in the aldehyde dehydrogenase gene. The gene encoding the CYP2D6 enzyme is localized on chromosome 22. By using restriction fragment length polymorphism analysis and the allele-specific polymerase chain reaction, three major mutant alleles were found in Caucasians. One of the most developed examples of clinical pharmacogenomics involves the polymorphism of thiopurine S-methyltransferase. The combined variants in drug metabolism and receptor gene are elaborated in the chapter. In the development of new pharmacogenetic tests, as for any other clinically applied test, assay sensitivity, specificity, and positive predictive value need to be scrutinized rigorously.

UR - http://www.scopus.com/inward/record.url?scp=75849143420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75849143420&partnerID=8YFLogxK

U2 - 10.1016/B978-012369417-1/50053-5

DO - 10.1016/B978-012369417-1/50053-5

M3 - Chapter

AN - SCOPUS:75849143420

SN - 9780123694171

SP - 179

EP - 195

BT - Principles of Clinical Pharmacology

PB - Elsevier Inc.

ER -